---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009865"
form_type: "8-K"
ticker: "OM"
cik: "0001484612"
company_name: "Outset Medical, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:50:24.425115+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Outset Medical prelim Q4 rev $28.9M; FY2025 rev $119.5M (+5% YoY); cash $173M; appoints Prange

## Summary
- Q4 2025 revenue ~$28.9M; full-year 2025 revenue $119.5M, up 5% from $113.7M in 2024.
- Year-end cash (incl. restricted cash & short-term investments) $173M; net cash used in ops <$50M vs $116M in 2024.
- Over 1,000 sites insource dialysis with Outset; ~1M treatments/year; cumulative >3M treatments on Tablo.
- Andrea Saia resigned from board effective Jan 9, 2026; Karen Prange appointed to board and Compensation Committee.
- Prange brings med device exec experience (Henry Schein, Boston Scientific, Johnson & Johnson).

## SEC filing metadata
- accession: 0001193125-26-009865
- form_type: 8-K
- ticker: OM
- cik: 0001484612
- company_name: Outset Medical, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484612/000119312526009865/0001193125-26-009865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484612/000119312526009865/om-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009865
- JSON: https://secwatch.observer/filing/0001193125-26-009865.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.